“Root%2Bcanal%2Btreatment”的搜索结果，显示 41-50 项，共有 6329 项

1. 神经科- 临床试验- 妙佑医疗国际

   To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...

2. 神经科- 临床试验- 妙佑医疗国际

   To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...

3. 神经科- 临床试验- 妙佑医疗国际

   ... (2) early onset non-Alzheimer's Disease (EO-nonAD) ... treatment and on-going care. ... treating patients with meningiomas that may have gotten bigger or grew back ...

4. 神经科- 临床试验- 妙佑医疗国际

   The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with ...

5. 神经科- 临床试验- 妙佑医疗国际

   To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...

6. 神经科- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine whether treatment ... (2) improves stroke outcomes at 3 months in ... canal irradiation (WVSCI) will maintain the ...

7. 神经科- 临床试验- 妙佑医疗国际

   ... treating participants with grade II-III meningioma that has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ...

8. CAR-T 细胞疗法计划- 临床试验- 妙佑医疗国际

   Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers. Rochester, Minn. A Phase 1b/2, open label, multi- ...

9. 神经科- 临床试验- 妙佑医疗国际

   Carotid revascularization for primary prevention of stroke (CREST-2) is two ... Medical management will be uniform for all randomized treatment groups and will be ...

10. 神经科- 临床试验- 妙佑医疗国际

    ... canal irradiation (WVSCI) will maintain the excellent 2-year progression free survival (PFS) rate as compared to ACNS0122. Also, to improve disease control ...